NCT05420220View on ClinicalTrials.gov

Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

July 15, 2022

Primary Completion Date

May 29, 2027

Study Completion Date

December 26, 2027

Conditions
Advanced Non-small Cell Lung Cancer
Interventions
BIOLOGICAL

KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein Injection)

5 mg/kg Q3W IV

COMBINATION_PRODUCT

Axitinib

5mg bid po

Trial Locations (6)

Unknown

RECRUITING

The Second Hospital of Anhui Medical University, Hefei

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

RECRUITING

Linyi Cancer Hospital, Linyi

RECRUITING

Yantai Yuhuangding Hospital, Yantai

NOT_YET_RECRUITING

Shanghai Chest Hospital, Shanghai

NOT_YET_RECRUITING

The first affiliated hospital, Zhejiang university, Hangzhou

All Listed Sponsors
lead

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

INDUSTRY